Exome Sequencing Finds Dual Diagnoses in 14 Children

Evidence

DNA sequencing identified two distinct genetic disease diagnoses in 14 children in a retrospective cohort of 872 unrelated children with suspected genetic disorders. Overall, 370 children (42.4%) received a molecular diagnosis—a diagnosis based on genetic findings. The 14 dual diagnoses represented 3.8% of that diagnosed group, not of everyone tested.

The pediatric exome study, published September 21, 2026, used whole-exome sequencing, which examines the protein-coding regions of DNA. Testing involved either the child alone or the child and both parents. Two clinical geneticists reviewed standardized descriptions of the children's clinical features. Dual diagnoses required two DNA changes classified as disease-causing or likely disease-causing, each corresponding to a distinct genetic disease.

The intestinal-failure study, published September 18, 2026, prospectively observed children younger than 18 at a single centre. Their intestinal function was insufficient to support their nutritional needs, requiring prolonged parenteral nutrition—nutrition delivered into the bloodstream. Of 37 identified children, 19 underwent transient elastography, a noninvasive test that estimates liver stiffness. Four (21.1%) met the study's threshold of at least 6.8 kilopascals, a unit of stiffness measurement, for fibrosis, or liver scarring.

Two of those four children died, compared with none of the 15 below the threshold: mortality of 50% versus 0%. The reported causes were intestinal-failure-related liver failure and respiratory failure; the child who died from respiratory failure also had impaired bile flow.

Analysis

Interpretation: The connection between these studies is methodological, not biological. Specialized testing identified small subgroups within two different pediatric cohorts. The genetic study identified distinct molecular diagnoses; the nutrition study identified children exceeding a liver-stiffness threshold whose validity in that population remains uncertain.

Those findings do not carry equivalent diagnostic certainty. Nor does identifying a subgroup establish that testing improves outcomes. The studies neither confirm one another nor demonstrate a shared disease mechanism.

Limitations

The genetics cohort was substantial, but its dual-diagnosis subgroup contained only 14 children. The functional effects of the reported DNA changes were not verified in laboratory experiments, and some links between genetic findings and clinical features need further validation. The findings characterize diagnoses rather than prove how paired variants act together.

The nutrition study was small, observational, and conducted at one centre. Only 19 of 37 identified children underwent elastography, creating concern about selection bias. The 6.8-kilopascal cutoff may not translate reliably to this population, and not all children had liver biopsies to compare stiffness classifications with tissue scarring. The fibrosis group was relatively younger and had more substantial coexisting illness, complicating the mortality comparison. Two deaths cannot establish that fibrosis caused the difference or that elastography reliably predicts survival.

What to watch

For the genetic findings, experiments testing the effects of the reported DNA changes could clarify currently unverified links to clinical features. For intestinal failure, a larger prospective study could compare the 6.8-kilopascal threshold with biopsy findings and assess mortality while accounting for age and coexisting illness. Agreement with tissue-confirmed scarring and a persisting adjusted mortality association would increase confidence; poor agreement or disappearance of that association would weaken it.